Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
Pneumonic adenocarcinoma (P-ADC) is defined as a primary lung ADC with a radiological
pneumonic presentation, usually referred to histologically as ADC with a mixed-invasive and
BAC predominant subtype in the 2004 WHO classification. Surgery is the best therapy for
resectable tumors since the effectiveness of chemotherapy is disappointing. In the advanced
P-ADC diffuse/multifocal types of BAC, epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) (gefitinib and erlotinib) have shown promise, with some rapid,
dramatic responses, possibly reflecting specific molecular differences from other non-small
cell lung carcinomas.
Phase:
Phase 2
Details
Lead Sponsor:
Intergroupe Francophone de Cancerologie Thoracique